[{"id":"11eb2a30-79d2-45b7-8ec7-2eee9474c40b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04957212","created_at":"2021-07-12T16:52:55.120Z","updated_at":"2025-02-25T12:28:13.875Z","phase":"Phase 3","brief_title":"Comparing Efficacy and Safety Between Pertuzumab® and Perjeta® in Neoadjuvant Treatment of HER2+ Breast Cancer","source_id_and_acronym":"NCT04957212","lead_sponsor":"Cinnagen","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • carboplatin • docetaxel • Perjeta (pertuzumab) • Pectuna (pertuzumab biosimilar)"],"overall_status":"Completed","enrollment":" Enrollment 214","initiation":"Initiation: 08/11/2018","start_date":" 08/11/2018","primary_txt":" Primary completion: 05/27/2020","primary_completion_date":" 05/27/2020","study_txt":" Completion: 05/27/2020","study_completion_date":" 05/27/2020","last_update_posted":"2024-07-26"}]